Enlivex Therapeutics (ENLV) Short Interest Ratio & Short Volume → Three basic steps to building the Ultimate Dividend Portfolio. (From DTI) (Ad) Free ENLV Stock Alerts $1.38 -0.02 (-1.43%) (As of 05/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends Enlivex Therapeutics Short Interest DataCurrent Short Interest230,600 sharesPrevious Short Interest263,200 sharesChange Vs. Previous Month-12.39%Dollar Volume Sold Short$327,452.00Short Interest Ratio1.3 Days to CoverLast Record DateMay 15, 2024Outstanding Shares18,600,000 sharesPercentage of Shares Shorted1.24%Today's Trading Volume266,281 sharesAverage Trading Volume145,724 sharesToday's Volume Vs. Average183% Short Selling Enlivex Therapeutics ? Sign up to receive the latest short interest report for Enlivex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENLV Short Interest Over TimeENLV Days to Cover Over TimeENLV Percentage of Float Shorted Over Time Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now Enlivex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2024230,600 shares $327,452.00 -12.4%N/A1.3 $1.42 4/30/2024263,200 shares $439,544.00 -5.6%N/A1.5 $1.67 4/15/2024278,700 shares $362,310.00 +17.9%N/A1.6 $1.30 3/31/2024236,400 shares $895,956.00 -9.6%N/A2.7 $3.79 3/15/2024261,500 shares $1.07 million +15.4%N/A2.4 $4.11 2/29/2024226,600 shares $703,593.00 +51.2%N/A2.2 $3.11 Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024149,900 shares $481,179.00 -6.6%N/A1.6 $3.21 1/31/2024160,500 shares $449,400.00 -13.7%N/A1.9 $2.80 1/15/2024185,900 shares $533,533.00 +32.5%N/A2.3 $2.87 12/31/2023140,300 shares $378,810.00 +36.0%N/A1.8 $2.70 12/15/2023103,200 shares $145,512.00 -6.3%N/A1.9 $1.41 11/30/2023110,100 shares $202,584.00 -0.9%N/A3.5 $1.84 11/15/2023111,100 shares $194,425.00 -6.2%N/A3.6 $1.75 10/31/2023118,400 shares $157,472.00 +13.1%N/A3.9 $1.33 10/15/2023104,700 shares $147,627.00 -8.1%N/A4.1 $1.41 9/30/2023113,900 shares $179,962.00 +4.4%N/A4.5 $1.58 9/15/2023109,100 shares $206,199.00 +3.4%N/A4.2 $1.89 8/31/2023105,500 shares $252,145.00 -9.3%N/A4.8 $2.39 8/15/2023116,300 shares $303,543.00 +2.4%N/A5.1 $2.61 7/31/2023113,600 shares $290,816.00 +8.6%N/A4.9 $2.56 7/15/2023104,600 shares $248,948.00 +2.5%N/A4.8 $2.38 6/30/2023102,100 shares $268,247.33 -20.2%N/A3.6 $2.63 6/15/2023128,000 shares $362,240.00 +5.6%N/A3.6 $2.83 5/31/2023121,200 shares $316,332.00 -5.8%N/A3.5 $2.61 5/15/2023128,700 shares $359,073.00 -1.2%N/A3.8 $2.79 4/30/2023130,200 shares $369,768.00 -4.6%N/A3.7 $2.84 4/15/2023136,400 shares $396,924.00 -15.7%N/A3.6 $2.91 3/31/2023161,700 shares $588,588.00 +0.5%N/A4.3 $3.64 3/15/2023160,900 shares $577,631.00 -1.3%N/A5.9 $3.59 2/28/2023163,000 shares $652,000.00 +0.9%N/A5.7 $4.00 2/15/2023161,500 shares $673,455.00 -8.8%N/A5.5 $4.17 1/31/2023177,100 shares $775,698.00 -2.9%N/A5.8 $4.38 1/15/2023182,300 shares $796,505.16 -4.8%N/A6.9 $4.37 12/30/2022191,400 shares $753,637.50 -0.5%N/A7.8 $3.94 12/15/2022192,400 shares $779,220.00 -11.5%N/A9.2 $4.05 11/30/2022217,500 shares $996,998.25 +16.9%N/A9 $4.58 11/15/2022186,000 shares $894,660.00 +0.1%N/A6.9 $4.81 10/31/2022185,800 shares $797,082.00 -3.8%N/A6.6 $4.29 10/15/2022193,100 shares $805,227.00 +1.2%N/A5.4 $4.17 9/30/2022190,900 shares $811,325.00 +4.5%N/A4.4 $4.25RE: Your account status (Ad)Your $200 MarketBeat account credit expires in less than twelve hours. Upgrade to MarketBeat All Access today and save $200 on your 2024-2025 MarketBeat premium subscription.Claim My Discount 9/15/2022182,700 shares $959,175.00 -5.4%N/A3.9 $5.25 8/31/2022193,100 shares $1.01 million -7.0%N/A4.2 $5.25 8/15/2022207,700 shares $1.08 million -9.5%N/A4.4 $5.22 7/31/2022229,600 shares $975,800.00 -8.4%N/A4 $4.25 7/15/2022250,600 shares $1.23 million -9.8%N/A3.8 $4.91 6/30/2022277,700 shares $1.26 million -2.3%N/A3.5 $4.52 6/15/2022284,300 shares $1.16 million -0.3%N/A3.5 $4.07 5/31/2022285,000 shares $1.43 million -9.2%N/A3.5 $5.01 5/15/2022313,900 shares $1.34 million -9.6%N/A4.1 $4.28 4/30/2022347,200 shares $1.98 million -3.9%N/A4.7 $5.69 4/15/2022361,300 shares $2.67 million +15.0%N/A5.9 $7.39 3/31/2022314,200 shares $1.76 million -2.2%N/A5.3 $5.59 3/15/2022321,300 shares $1.63 million -10.4%N/A5.3 $5.06 2/28/2022358,500 shares $1.92 million -4.0%N/A4.9 $5.35 2/15/2022373,500 shares $1.99 million +2.8%N/A4.7 $5.34 1/31/2022363,200 shares $1.94 million +8.2%N/A4.2 $5.34 1/15/2022335,700 shares $1.97 million -8.3%N/A3.7 $5.87 12/31/2021365,900 shares $2.29 million +0.1%N/A4.2 $6.25 12/15/2021365,400 shares $2.40 million -3.6%N/A4.4 $6.56 11/30/2021379,000 shares $2.65 million +7.0%N/A5 $7.00 11/15/2021354,200 shares $2.91 million +9.9%N/A3.5 $8.21 10/29/2021322,200 shares $2.65 million +4.5%N/A1 $8.24 10/15/2021308,300 shares $2.86 million -13.0%N/A0.9 $9.28 9/30/2021354,300 shares $3.50 million -8.0%N/A1.1 $9.88 9/15/2021385,200 shares $4.21 million -8.0%N/A1.2 $10.92 8/31/2021418,500 shares $5.80 million +114.2%N/A1.3 $13.86 8/13/2021195,400 shares $1.99 million +38.0%N/A0.7 $10.17 7/30/2021141,600 shares $1.08 million No Change1.2%2.1 $7.60 7/15/2021141,600 shares $1.07 million +0.9%1.2%1.8 $7.54 6/30/2021140,400 shares $1.25 million +4.0%1.2%1.6 $8.90 6/15/2021135,000 shares $1.32 million +14.9%1.1%1.5 $9.80 5/28/2021117,500 shares $1.10 million -28.6%1.0%1.1 $9.37 5/14/2021164,500 shares $1.42 million +26.4%N/A1.1 $8.61 4/30/2021130,100 shares $1.57 million +94.2%N/A0.3 $12.10 4/15/202167,000 shares $725,610.00 -18.8%N/A0.2 $10.83 3/31/202182,500 shares $874,500.00 -17.6%N/A0.2 $10.60 3/15/2021100,100 shares $1.44 million +5.2%1.0%0.2 $14.40 2/26/202195,200 shares $1.44 million +64.4%1.1%0.2 $15.11 2/12/202157,900 shares $1.22 million -76.6%0.7%0.1 $21.09 1/29/2021246,900 shares $2.93 million +13.8%3.2%0.7 $11.85 1/15/2021217,000 shares $2.23 million +7.1%2.9%1 $10.29 12/31/2020202,600 shares $1.87 million -24.9%2.7%0.7 $9.22 12/15/2020269,700 shares $2.65 million +165.2%3.5%0.2 $9.83 11/30/2020101,700 shares $876,654.00 -38.2%1.3%0.1 $8.62 11/15/2020164,600 shares $1.53 million -13.1%2.2%0.1 $9.28 10/30/2020189,500 shares $2.23 million -53.7%2.5%0.2 $11.75 10/15/2020408,900 shares $5.41 million +1,497.3%5.4%0.4 $13.23 9/30/202025,600 shares $152,064.00 +22.5%0.3%0 $5.94 9/15/202020,900 shares $108,262.00 -57.1%0.3%0.3 $5.18 8/31/202048,700 shares $252,753.00 +429.4%0.6%0.5 $5.19RE: Your account status (Ad)Your $200 MarketBeat account credit expires in less than twelve hours. Upgrade to MarketBeat All Access today and save $200 on your 2024-2025 MarketBeat premium subscription.Claim My Discount 8/14/20209,200 shares $48,668.00 -59.1%0.1%0.1 $5.29 7/31/202022,500 shares $122,850.00 +10.3%0.3%0.2 $5.46 7/15/202020,400 shares $104,040.00 +88.9%0.3%0.2 $5.10 6/30/202010,800 shares $65,448.00 -6.1%0.1%0.1 $6.06 6/15/202011,500 shares $62,560.00 -48.0%0.2%0.1 $5.44 5/29/202022,100 shares $117,130.00 +71.3%0.3%0.2 $5.30 5/15/202012,900 shares $62,178.00 +152.9%0.2%0.1 $4.82 4/30/20205,100 shares $27,999.00 -67.1%0.1%0 $5.49 4/15/202015,500 shares $86,800.00 -17.6%0.2%0.1 $5.60 3/31/202018,800 shares $105,468.00 -69.6%0.3%0.1 $5.61 3/13/202061,900 shares $282,264.00 +302.0%1.4%0.2 $4.56 2/28/202015,400 shares $63,448.00 -54.0%0.3%0.1 $4.12 2/14/202033,500 shares $192,960.00 +805.4%0.8%0.5 $5.76 1/31/20203,700 shares $31,450.00 -32.7%0.1%0.2 $8.50 1/15/20205,500 shares $45,100.00 +10.0%0.1%0.2 $8.20 12/31/20195,000 shares $45,500.00 +11.1%0.1%0.1 $9.10 ENLV Short Interest - Frequently Asked Questions What is Enlivex Therapeutics' current short interest? Short interest is the volume of Enlivex Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 230,600 shares of ENLV short. Learn More on Enlivex Therapeutics' current short interest. What is a good short interest ratio for Enlivex Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENLV shares currently have a short interest ratio of 1.0. Learn More on Enlivex Therapeutics's short interest ratio. Is Enlivex Therapeutics' short interest increasing or decreasing? Enlivex Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 230,600 shares, a drop of 12.4% from the previous total of 263,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Enlivex Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Enlivex Therapeutics: Aprea Therapeutics, Inc. (0.68%), Apollomics, Inc. (0.20%), Oncternal Therapeutics, Inc. (0.87%), Bolt Biotherapeutics, Inc. (8.82%), ImmunoPrecise Antibodies Ltd. (0.93%), Biora Therapeutics, Inc. (3.85%), JanOne Inc. (2.92%), Viracta Therapeutics, Inc. (2.42%), Lisata Therapeutics, Inc. (0.16%), Unity Biotechnology, Inc. (2.02%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Enlivex Therapeutics stock? Short selling ENLV is an investing strategy that aims to generate trading profit from Enlivex Therapeutics as its price is falling. ENLV shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enlivex Therapeutics? A short squeeze for Enlivex Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ENLV, which in turn drives the price of the stock up even further. How often is Enlivex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENLV, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Aprea Therapeutics Short Squeeze Apollomics Short Squeeze Oncternal Therapeutics Short Squeeze Bolt Biotherapeutics Short Squeeze ImmunoPrecise Antibodies Short Squeeze Biora Therapeutics Short Squeeze JanOne Short Squeeze Viracta Therapeutics Short Squeeze Lisata Therapeutics Short Squeeze Unity Biotechnology Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENLV) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWall Street Legend Warns: "A Strange Day Is Coming to America"Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.